



## EOS imaging Announces Two Installations at New York-Presbyterian Hospital

*The Allen Hospital Spinal Surgery Center and Morgan Stanley Pediatric Hospital  
are now equipped with the EOS® solution*

Paris, July 22, 2015 – EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging and associated solutions, today announced two EOS® system installations at New York-Presbyterian Hospital, a world-renowned hospital. The devices have been installed at New York-Presbyterian/Morgan Stanley Children's Hospital and New York-Presbyterian/Allen Hospital.

The two EOS® installations at the New York-Presbyterian campuses are concurrent with the recent recruitment of three prominent spinal surgeons as part of an expansion of the hospital's orthopedics program and the creation of a state-of-the-art comprehensive spinal surgery hospital in northern Manhattan.

New York-Presbyterian was recently ranked first in the New York metropolitan area and is consistently named to the honor roll of best hospitals in the nation by *U.S. News & World Report*.

Marie Meynadier, CEO of EOS imaging, said, "We are proud that New York-Presbyterian Hospital, the third hospital group to adopt our unique technology in the Manhattan area, has selected EOS® to support their leadership position in orthopedics for both pediatric and adult patients in New York City. This double installation echoes the strong adoption momentum of our solution across the US."

The EOS® system provides full-body stereo-radiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans, as well as related software solutions. The new EOS Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA principle (As Low As Reasonably Achievable) by bringing pediatric spine follow up exams at a dose level equivalent to a week of natural background radiation on Earth.

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit <http://www.eos-imaging.com/>.

**EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.**



EOS imaging is listed on Compartment C of Euronext Paris  
ISIN: FR0011191766 – Ticker: EOSI

Next press release: 2015 1<sup>st</sup> half results, on September 1st, 2015 (after market).



3D orthopaedic imaging,  
see better to treat better



DON'T GUESS. SEE.

Press Release

**About EOS imaging:**

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled Georges Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 48 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and Singapore.

**Contacts:**

**Anne Renevot**

CFO

Ph: +33 (0)1 55 25 61 24

[investors@eos-imaging.com](mailto:investors@eos-imaging.com)

**NewCap**

Financial communication and investor relations

Antoine Denry/ Pierre Laurent

Ph: +33 (0)1 44 71 94 91

[eosimaging@newcap.fr](mailto:eosimaging@newcap.fr)

**The Ruth Group (US)**

Press relations / Melanie Sollid-Penton

Ph: 646-536-7023

[msollid@theruthgroup.com](mailto:msollid@theruthgroup.com)